KROS Keros Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Keros Therapeutics Inc reported revenue of $0 (down 100.0% from a year earlier), net income of −$28.7M and diluted EPS of −$1.45; over the last four quarters revenue was $14.5M and net income −$83.2M; for the fiscal year ended December 2025 revenue was $244M.
KROS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $244M, gross profit n/a, operating income $67.6M, net income $87.0M (margin 35.7%), EPS $2.30
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$211M, net income −$187M (margin n/a), EPS −$5.00
- Fiscal year ended Dec 2023: revenue $151K, gross profit n/a, operating income −$170M, net income −$153M (margin -101319.2%), EPS −$5.20
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$115M, net income −$105M (margin n/a), EPS −$4.15
- Fiscal year ended Dec 2021: revenue $20.1M, gross profit n/a, operating income −$56.4M, net income −$58.7M (margin -292.3%), EPS −$2.52
KROS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$28.7M, EPS −$1.45
- Quarter ended Mar 31, 2026: revenue $32.0K (down 100.0% year over year), net income −$23.7M, EPS −$1.21
- Quarter ended Dec 31, 2025 (from the annual report): revenue $380K, net income −$23.5M, EPS −$0.38
- Quarter ended Sep 30, 2025: revenue $14.1M, net income −$7.28M, EPS −$0.18
- Quarter ended Jun 30, 2025: revenue $18.2M, net income −$30.7M, EPS −$0.76
- Quarter ended Mar 31, 2025: revenue $211M, net income $148M, EPS $3.62
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$46.0M, EPS −$1.13
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$53.0M, EPS −$1.41
- Quarter ended Jun 30, 2024: revenue $0, net income −$45.3M, EPS −$1.25
- Quarter ended Mar 31, 2024: revenue $0, net income −$43.1M, EPS −$1.21
- Quarter ended Dec 31, 2023 (from the annual report): revenue $143K, net income −$40.2M, EPS −$1.34
- Quarter ended Sep 30, 2023: revenue $8.00K, net income −$39.4M, EPS −$1.33
- Quarter ended Jun 30, 2023: revenue $0, net income −$37.5M, EPS −$1.27
- Quarter ended Mar 31, 2023: revenue $0, net income −$35.8M, EPS −$1.26
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$29.7M, EPS −$1.09
- Quarter ended Sep 30, 2022: revenue $0, net income −$23.5M, EPS −$0.92
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$27.3M, EPS −$1.13
- Quarter ended Mar 31, 2022: revenue n/a, net income −$24.2M, EPS −$1.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$6.94M, EPS −$0.30
- Quarter ended Sep 30, 2021: revenue $0, net income −$20.3M, EPS −$0.87
KROS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $108M, share buybacks $375M
- Fiscal year ended Dec 2024: operating cash flow −$161M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$125M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$70.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$62.1M, share buybacks n/a
KROS balance sheet
- Jun 30, 2026: cash $258M, total assets $288M, total liabilities $25.3M, shareholders' equity $262M
- Mar 31, 2026: cash $281M, total assets $312M, total liabilities $26.7M, shareholders' equity $286M
- Dec 31, 2025: cash $287M, total assets $338M, total liabilities $34.9M, shareholders' equity $303M
- Sep 30, 2025: cash $693M, total assets $743M, total liabilities $39.2M, shareholders' equity $704M
- Jun 30, 2025: cash $690M, total assets $757M, total liabilities $50.4M, shareholders' equity $707M
- Mar 31, 2025: cash $721M, total assets $785M, total liabilities $55.7M, shareholders' equity $729M
- Dec 31, 2024: cash $560M, total assets $616M, total liabilities $44.3M, shareholders' equity $572M
- Sep 30, 2024: cash $531M, total assets $579M, total liabilities $46.4M, shareholders' equity $533M
What is KROS's revenue?
Keros Therapeutics Inc reported $14.5M of revenue over its last four quarters, through June 30, 2026.
Is KROS profitable?
No. Keros Therapeutics Inc lost $83.2M over the last four quarters.
What is KROS's EPS?
Diluted earnings per share over the last four quarters were −$3.22; −$1.45 in the latest quarter.